Is Amkay Products overvalued or undervalued?

As of 26 August 2025, the valuation grade for Amkay Products has moved from very expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 14.51, an EV to EBITDA of 13.03, and a ROE of 33.40%.
In comparison to its peers, Amkay Products stands out as more reasonably priced, especially when looking at Poly Medicure with a PE of 59.04 and Blue Jet Health at 34.2. This indicates that Amkay Products is positioned favorably within its industry. Despite a recent decline in stock performance, with a year-to-date return of -10.26% compared to a Sensex return of 3.39%, the company's current valuation suggests it may be a solid investment opportunity moving forward.